LONDON, May 21, 2026 /PRNewswire/ -- Markel Insurance, the insurance operation within Markel Group Inc. (NYSE:MKL), today announced the appointment of Danny O'Donoghue to Head of Fine Art & Specie, effective immediately.

In his new role, O'Donoghue will be responsible for leading the strategic and sustainable expansion of Markel's Fine Art & Specie portfolio to further enhance the organisation's position in London as a leading Fine Art & Specie insurer. His principal duties will include identifying, assessing and underwriting complex risks across four key areas – Fine Art, Specie, Jewellers Block and Cash in Transit – while supporting underwriters in his team with their professional development.

Alongside these duties, O'Donoghue will foster broker relationships and work closely with Markel's Claims and Actuarial functions, where he'll keep abreast of industry developments, ensuring coverage remains tailored for broker partners and insureds. Furthermore, he'll identify collaborative opportunities across the business' international Fine Art & Specie teams to enhance broker service levels and drive further profitable growth.

O'Donoghue will be based in London, reporting to Dan McCarthy, Director of Marine at Markel International.

McCarthy commented: "Rising asset values, a surge in high-profile thefts and more frequent natural catastrophes are creating new risks while intensifying existing exposures for galleries, jewellers and private collectors. Danny's achievements are underpinned by an entrepreneurial mindset, which will be critical as we continue to deliver best-in-class underwriting services, support and standards to our brokers and clients.

"We're delighted to have someone of Danny's caliber join Markel's Fine Art & Specie team here in London. With his significant expertise in managing and scaling large Fine Art Specie portfolios, we're confident he'll be able to take ours to new heights, elevating our leadership position in the London Market."

O'Donoghue said: "I'm delighted to be joining Markel in my new role as Head of Fine Art & Specie. Opportunities like this don't come around often, but Markel really stood out to me. I saw strong cultural alignment, a clear and unified proposition and a well-defined strategic direction – all of which I believe are essential building blocks to continue growing the team and portfolio for years to come. 

"I'm excited to drive the continued expansion of Markel's lead specialist capabilities across the Fine Art & Specie market and support our brokers and clients across an evolving and complex risk landscape."

O'Donoghue possesses more than 15 years' underwriting experience, spending 13 of them specialising in Fine Art & Specie insurance. Previously, he was employed at Talbot as Head of Fine Art & Specie, where he led global strategy and execution for Fine Art & Specie across Lloyd's Syndicate 1183 and AIG company platforms. Prior to this position, he worked at Aspen for more than 10 years as a Senior Fine Art & Specie Underwriter.

About Markel Insurance

We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide. 

Photo - https://mma.prnewswire.com/media/2984338/Markel_Danny_ODonoghue.jpg

Logo - https://mma.prnewswire.com/media/2090808/Markel_primary_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/markel-appoints-danny-odonoghue-to-head-of-fine-art--specie-for-its-london-operations-302777951.html

Apotheken in Deutschland erhalten deutlich mehr Handlungsspielraum: Der Bundesrat hat eine Reform der schwarz-roten Koalition passieren lassen, die die Rolle der Offizinen im Gesundheitswesen spürbar aufwertet. Ziel ist es, die wohnortnahe Versorgung zu stärken, Wartezeiten in Arztpraxen zu reduzieren und Prävention sowie Früherkennung auszubauen. Das Paket war zuvor bereits vom Bundestag beschlossen worden.

Kern der Reform ist ein erweitertes Leistungsangebot in Apotheken. Künftig sollen dort zusätzliche Vorsorge- und Früherkennungsuntersuchungen möglich sein, etwa zu Herz-Kreislauf-Erkrankungen, Diabetes oder Angeboten rund um das Rauchen. Apotheken können damit stärker als bisher in der Prävention ansetzen und Risiken identifizieren, bevor es zu manifesten Erkrankungen kommt.

Auch im Impfbereich werden die Kompetenzen ausgeweitet. Neben den bereits etablierten Grippe- und Corona-Impfungen dürfen Apotheken künftig alle Schutzimpfungen mit sogenannten Totimpfstoffen anbieten, darunter etwa Tetanus. Ergänzend werden Blutabnahmen erlaubt, etwa um Medikamentenwirkungen zu kontrollieren. Damit rücken Apotheken näher an klassische ärztliche Tätigkeitsfelder heran, ohne diese vollständig zu ersetzen.

Besonders sensibel ist die neue Möglichkeit, in eng begrenzten Fällen verschreibungspflichtige Medikamente ohne ärztliche Verordnung abzugeben. Erlaubt ist künftig die einmalige Ausgabe der kleinsten Packungsgröße auf Selbstzahlerbasis, wenn ein Arzneimittel seit längerem eingenommen wird und die Fortführung der Therapie keinen Aufschub erlaubt. Die Regelung soll Versorgungslücken schließen, etwa wenn ein Rezept nicht rechtzeitig vorliegt, und bleibt zugleich strikt begrenzt, um Missbrauch zu vermeiden.